Novartis Snaps Up KRAS Inhibitor R&D
Difficult-To-Target Oncogenic Proteins Yield To Drug Discovery
Executive Summary
Novartis has taken an option on novel inhibitors of the KRAS cell signaling pathway while it funds the drug discovery research at the Cancer Research UK’s Beatson Institute.
You may also be interested in...
Amgen’s KRAS Inhibitor Shows Durability; Pivotal Data Possible This Year
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.
Merck Joins KRAS Stampede In Deal With Otsuka Affiliates
Merck & Co. is paying $50m up front to combine preclinical KRAS-target cancer compound pipelines with Astex and Taiho, both affiliates of Japan’s Otsuka. The two biotechs could realize up to $2.5bn in earnouts under the collaboration.
Early Assets Excite At Novartis R&D Day
NIBR chief Jay Bradner tells Scrip that the Swiss major's focus is on developing first in class therapies rather than 'fast-follower' research seen across the biopharma sector.